ALCAM Expression in Thyroid Tumors
Author Information
Author(s): Miccichè Francesca, Da Riva Luca, Fabbi Marina, Pilotti Silvana, Mondellini Piera, Ferrini Silvano, Canevari Silvana, Pierotti Marco A., Bongarzone Italia
Primary Institution: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Hypothesis
The study investigates the expression and shedding of ALCAM in thyroid tumors and its potential role in tumor biology.
Conclusion
The study found that ALCAM is overexpressed in thyroid tumors and may play a significant role in their biology.
Supporting Evidence
- ALCAM was found to be overexpressed in thyroid tumors compared to normal tissues.
- Western blot analysis showed distinct ALCAM isoforms in thyroid cancer cell lines.
- ADAM17/TACE was identified as a key enzyme involved in ALCAM shedding.
- ALCAM shedding was increased by treatments with PMA and ionomycin.
- Immunohistochemistry revealed higher ALCAM expression in tumor samples than in normal thyroid tissues.
- Silencing ADAM17/TACE reduced ALCAM release and cell migration in thyroid cancer cells.
- ALCAM expression patterns varied between different types of thyroid tumors.
- ALCAM may play a role in the invasiveness and progression of thyroid tumors.
Takeaway
ALCAM is a protein that is found in high amounts in thyroid tumors, and it might help these tumors grow and spread.
Methodology
The study used western blot analysis, immunohistochemistry, and cell line experiments to assess ALCAM expression and shedding.
Potential Biases
Potential bias in sample selection and analysis methods could affect the results.
Limitations
The study primarily focused on a limited number of thyroid tumor samples and may not represent all thyroid cancers.
Participant Demographics
The study involved 22 patients with thyroid tumors, including papillary and medullary types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website